Citations

Clear

1053 citation(s) found for "Andre, F".

RNA‐seq analysis of clinical‐grade osteochondral allografts reveals activation of early response genes
Yang, Lin , Lewallen, Eric A. , Camilleri, Emily T. , Bonin, Carolina A. , Jones, Dakota L. , Dudakovic, Amel , Galeano‐Garces, Catalina , Wang, Wei , Karperien, Marcel , Larson, A. Noelle , Dahm, Diane L., Levy, Bruce A. , Smith, Jay , Ryssman, Daniel B., Im, Hee‐Jeong , Wijnen, André J. van , Riester, Scott M. , Krych, Aaron J. , Camilleri, Emily , Lin, Yang , Larson, Annalise N, van Wijnen, Andre J, Stuart, Michael J. , Westendorf, Jennifer J. , van Wijnen, Andre J , Krych, Aaron J , Larson, A Noelle , Camilleri, Emily

Mayo Clinic

Journal of Orthopaedic Research | February 25, 2016 | Volume: 34 | Issue: 11 | Pages: 1950-1959

10.1002/jor.23209 | PMID 26909883 Get It

ABSTRACTPreservation of osteochondral allografts used for transplantation is critical to ensure favorable outcomes for patients after surgical treatment of cartilage defects. To study the biological effects of protocols currently used for cartilage storage, we investigated differences in gene expression between stored allograft cartilage and fresh cartilage from living donors using high throughput molecular screening strategies. We applied next generation RNA sequencing (RNA‐seq) and real‐time reverse transcription quantitative polymerase chain reaction (RT‐qPCR) to assess genome‐wide differences in mRNA expression between stored allograft cartilage and fresh cartilage tissue from living donors. Gene ontology analysis was used to characterize biological pathways associated with differentially expressed genes. Our studies establish reduced levels of mRNAs encoding cartilage related extracellular matrix (ECM) proteins (i.e., COL1A1, COL2A1, COL10A1, ACAN, DCN, HAPLN1, TNC, and COMP) in stored cartilage. These changes occur concomitantly with increased expression of “early response genes” that encode transcription factors mediating stress/cytoprotective responses (i.e., EGR1, EGR2, EGR3, MYC, FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, and JUND). The elevated expression of “early response genes” and reduced levels of ECM‐related mRNAs in stored cartilage allografts suggests that tissue viability may be maintained by a cytoprotective program that reduces cell metabolic activity. These findings have potential implications for future studies focused on quality assessment and clinical optimization of osteochondral allografts used for cartilage transplantation. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1950–1959, 2016.
Big Data Transforms Discovery–Utilization Therapeutics Continuum
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Clinical Pharmacology & Therapeutics | February 20, 2016 | Volume: 99 | Issue: 3 | Pages: 250-254

10.1002/cpt.322 | PMID 26888297 Get It

Enabling omic technologies adopt a holistic view to produce unprecedented insights into the molecular underpinnings of health and disease, in part, by generating massive high‐dimensional biological data. Leveraging these systems‐level insights as an engine driving the healthcare evolution is maximized through integration with medical, demographic, and environmental datasets from individuals to populations. Big data analytics has accordingly emerged to add value to the technical aspects of storage, transfer, and analysis required for merging vast arrays of omic‐, clinical‐, and eco‐datasets. In turn, this new field at the interface of biology, medicine, and information science is systematically transforming modern therapeutics across discovery, development, regulation, and utilization.
Nodular Fasciitis of the Orbit: A Case Report Confirmed by Molecular Cytogenetic Analysis
Anzeljc, Andrew J., Oliveira, André M. , Kim, Hee Joon , Hayek, Brent , Grossniklaus, Hans E.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | February 14, 2016 | Volume: 33 | Issue: 3S | Pages: S152-S155

10.1097/iop.0000000000000649 | PMID 26882059 Get It

Nodular fasciitis is a benign fibroblastic proliferation typically found in the subcutaneous tissue or superficial fascia of the extremities that is often confused for malignancy. These lesions rarely occur on the eyelids and ocular adnexa and are seldom analyzed by ophthalmic pathologists. USP6 gene rearrangement has been recently demonstrated in nodular fasciitis and this rearrangement may lead to the formation of a fusion gene MYH9-USP6 in some cases. Herein, the authors describe a 38-year-old woman with a 6-month history of a progressively enlarging mass beneath her right medial upper eyelid. Histopathologic analysis of the excisional biopsy confirmed classic features of nodular fasciitis. Molecular cytogenetic analysis revealed a rearrangement of the USP6 locus, confirming the diagnosis of benign nodular fasciitis.
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database
Renfro, Lindsay A. , Kerr, David , Gramont, Aimery de , André, Thierry , Guthrie, Katherine A. , Labianca, Roberto , Francini, Guido, Seitz, J. F., O’Callaghan, Chris J. , Twelves, Chris , Haller, Daniel G. , Yothers, Greg , Cheung, Winson Y, de Gramont, Aimery, Saltz, Leonard B. , O'Callaghan, Chris, van Cutsem, Eric, Cheung, Winson Y. , Grothey, Axel , Alberts, Steven R. , Cutsem, Eric Van , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | February 9, 2016 | Volume: 34 | Issue: 11 | Pages: 1182-1189

10.1200/jco.2015.65.1158 | PMID 26858337 Get It

Purpose Factors associated with early mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly understood. We aimed to characterize the determinants of early mortality in a large cohort of colon cancer trial participants. Methods A pooled analysis of 37,568 patients in 25 randomized trials of adjuvant systemic therapy was conducted. Multivariable logistic regression models with several definitions of early mortality (30, 60, and 90 days, and 6 months) were constructed, adjusting for clinically and statistically significant variables. A nomogram for 6-month mortality was developed and validated. Results Median age among patients was 61 years, patient demographics included 54% men and 90% White, 29% and 71% had stage II and III disease, respectively, and 79%, 20%, and 1% had an Eastern Cooperative Oncology Group performance status (PS) of 0, 1, and ≥ 2, respectively. Early mortality was low: 0.3% at 30 days, 0.6% at 60 days, 0.8% at 90 days, and 1.4% at 6 months. Of those patients who died by 6 months post–random assignment, 40% had documented disease recurrence prior to death. Early disease recurrence was associated with a markedly increased risk of death during the first 6 months post-treatment (hazard ratio, 82.6; 95%CI, 66.9 to 102.1). In prognostic analyses, advanced age, male sex, poorer PS, increasing ratio of positive to examined lymph nodes, earlier decade of enrollment, and higher tumor stage and grade predicted a greater likelihood of early mortality, whereas treatment received was not strongly predictive. A multivariable model for 6-month mortality showed strong optimism-adjusted discrimination (concordance index, 0.73) and calibration. Conclusion Early mortality was infrequent but more prevalent in patients with advanced age and a PS of ≥ 2, underscoring the need to carefully consider the risk-to-benefit ratio when making treatment decisions in these subgroups.
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Choueiri, Toni K. , Fay, André P. , Velasco, Guillermo de , Tyburczy, Magdalena E. , Hamieh, Lana , Albigès, Laurence , Ho, Thai H. , Song, Jiaxi , Pignon, Jean‐Christophe , Barrios, Pablo M. , Michaelson, M. Dror , Krajewski, Katherine M. , Porta, Camillo , Pal, Sumanta K. , Heng, Daniel Y.C., Gray, Kathryn P. , Kwiatkowski, David J. , Rini, Brian I. , Thorner, Aaron R. , Agarwal, Neeraj , Van Allen, Eliezer M , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Ho, Thai , Choueiri, Toni K

Mayo Clinic

Clinical Cancer Research | February 1, 2016 | Volume: 22 | Issue: 10 | Pages: 2445-2452

10.1158/1078-0432.ccr-15-2631 | PMID 26831717 Get It

Abstract Purpose: We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC). Experimental Design: We studied a cohort of mRCC patients who were treated with mTOR inhibitors with distinct clinical outcomes. Tumor DNA from 79 subjects was successfully analyzed for mutations using targeted next-generation sequencing of 560 cancer genes. Responders were defined as those with partial response (PR) by RECIST v1.0 or stable disease with any tumor shrinkage for 6 months or longer. Nonresponders were defined as those with disease progression during the first 3 months of therapy. Fisher exact test assessed the association between mutation status in mTOR pathway genes and treatment response. Results: Mutations in MTOR, TSC1, or TSC2 were more common in responders, 12 (28%) of 43, than nonresponders, 4 (11%) of 36 (P = 0.06). Mutations in TSC1 or TSC2 alone were also more common in responders, 9 (21%), than nonresponders, 2(6%), (P = 0.05). Furthermore, 5 (42%) of 12 subjects with PR had mutations in MTOR, TSC1, or TSC2 compared with 4 (11%) of 36 nonresponders (P = 0.03). Eight additional non-mTOR pathway genes were found to be mutated in at least 4 of 79 tumors (5%); none were associated positively with response. Conclusions: In this cohort of mRCC patients, mutations in MTOR, TSC1, or TSC2 were more common in patients who experienced clinical benefit from rapalogs than in those who progressed. However, a substantial fraction of responders (24 of 43, 56%) had no mTOR pathway mutation identified. Clin Cancer Res; 22(10); 2445–52. ©2016 AACR. See related commentary by Voss and Hsieh, p. 2320
Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release
Arsoy, Diren , Riester, Scott M. , Wijnen, André J. van , Morrey, B.F. , Barlow, Jonathan D. , Morrey, Mark E. , Hartzler, Robert U. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

Bone & Joint Research | January 27, 2016 | Volume: 5 | Issue: 1 | Pages: 11-17

10.1302/2046-3758.51.2000593 | PMID 26813567 Get It

Aims Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (sd) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties. Cite this article: M. P. Abdel. Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis. Bone Joint Res 2016;5:11–17. doi: 10.1302/2046-3758.51.2000593
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Renfro, Lindsay A. , Allegra, Carmen J. , André, Thierry , Gramont, Aimery de , Haller, Daniel G. , Yothers, Greg , Shah, Manish A, de Gramont, Aimery, Schmoll, Hans‐Joachim , Shah, Manish A , Alberts, Steven R. , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | January 26, 2016 | Volume: 34 | Issue: 8 | Pages: 843-853

10.1200/jco.2015.63.0558 | PMID 26811529 Get It

Purpose Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
Clinical Development Plan for Regenerative Therapy in Heart Failure
Behfar, Atta , Filippatos, Gerasimos , Terzic, André , Behfar, Atta

Mayo Clinic

European Journal of Heart Failure | January 22, 2016 | Volume: 18 | Issue: 2 | Pages: 142-144

10.1002/ejhf.479 | PMID 26800140 Get It

Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, Thomas, Gimona, Mario , Aigner, Ludwig , Börger, Verena , Buzás, Edit I. , Camussi, Giovanni , Chaput, Nathalie , Chatterjee, Devasis, Court, Felipe A. , Portillo, Hernando A. del , Fais, Stefano , Felderhoff‐Mueser, Ursula, Fraile, Lorenzo , Gho, Yong Song , Görgens, André , Gupta, Ramesh C. , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Horn, Peter A. , Kramer, Boris W. , Krämer‐Albers, Eva‐Maria , Laner‐Plamberger, Sandra , Laitinen, Saara , Leonardi, Tommaso , Lorenowicz, Magdalena J. , Lim, Sai Kiang , Lötvall, Jan , Maguire, Casey A. , Marcilla, Antonio , Nazarenko, Irina , Ochiya, Takahiro , Pedersen, Shona , Pòcsfalvi, Gabriella , Quesenberry, Peter J. , Reischl, Ilona , Rivera, Francisco J. , Sanzenbacher, Ralf, Schallmoser, Katharina , Slaper‐Cortenbach, Ineke , Strunk, Dirk , Vader, Pieter , Balkom, Bas W. M. van , Wauben, Marca H. M. , Andaloussi, Samir EL , Théry, Clotilde , Rohde, Eva , Giebel, Bernd , O’Driscoll, Lorraine , Falcón‐Pérez, Juan Manuel , Hermann, Dirk Matthias , Kleijn, Dominique P.V. de , Kordelas, Lambros , Patel, Tushar , Pluchino, Stefano , Tonn, Torsten , Leonardi, Tommaso , Nazarenko, Irina , Hill, Andrew F , Buzas, Edit I , Giebel, Bernd

Mayo Clinic

Journal of Extracellular Vesicles | December 31, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.30087 | PMID 26725829 Get It

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell‐derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti‐tumour therapy, (b) pathogen vaccination, (c) immune‐modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV‐based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV‐based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME‐HaD), summarize recent developments and the current knowledge of EV‐based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
Internal Fixation of Unstable Osteochondritis Dissecans in the Skeletally Mature Knee with Metal Screws
Barrett, Ian J. , King, Alexander H. , Riester, Scott M. , Wijnen, André J. van , Levy, Bruce A. , Krych, Aaron J. , Barrett, Ian, Riester, Scott, van Wijnen, Andre, Stuart, Michael J. , van Wijnen, Andre J , Krych, Aaron J

Mayo Clinic

CARTILAGE | December 30, 2015 | Volume: 7 | Issue: 2 | Pages: 157-162

10.1177/1947603515622662 | PMID 27047638 Get It

Purpose Several bioabsorbable and metal options are available for internal fixation of an unstable osteochondritis dissecans (OCD) lesion, but currently there are little data on outcomes with metal headless compression screws in the adult knee. The purpose of this study was to determine (1) the radiographic healing rates, (2) midterm clinical outcomes, and (3) comparison between healed and unhealed OCD fragments after use of headless metal compression screws for the treatment of unstable OCD lesions in the knees of skeletally mature patients. Methods Retrospective chart review for all skeletally mature patients who presented with unstable femoral condyle OCD lesions of the knee was conducted. All patients underwent open or arthroscopic reduction and internal fixation using headless metal compression screws. Preoperative and postoperative radiographs were reviewed with healing defined as radiographic evidence of union of the OCD progeny fragment with the condyle. Clinical outcome data were collected retrospectively using 3 validated outcome scores: International Knee Documentation Committee (IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Marx. Results Twenty-two knees in 22 patients with a mean age of 21 years (range= 14-37 years) were followed for an average of 8.7 years (range = 2-22 years). Metal, headless, cannulated compression screws were used in all 22 cases. At a mean of 31 months postoperatively (range = 2-262), fragment union was observed in 18 knees (82%). The remaining 4 knees (18%) required loose fragment excision and hardware removal at a mean of 9 months (range = 2-16 months) postoperatively. Mean postoperative Marx score was 7 (range = 0-16), the mean postoperative IKDC score was 85 (range = 62-100), and mean KOOS scores included KOOS Pain (93; range = 69-100), KOOS Symptoms (86; range = 71-100), KOOS ADL (98; range = 90-100), KOOS Sports (82; range = 50-100), and KOOS QOL (76; range = 50-100). Conclusion Headless metal compression screws provide a satisfactory union rate for treatment of unstable OCD lesions of the femoral condyles in skeletally mature patients. Patients achieving union have good knee function, maintain satisfactory activity levels, and have superior knee outcomes compared with those that failed to heal after fixation at mid to long-term follow-up.